The patient is already taking telmisartan 80 mg daily and amlodipine 10 mg daily; what additional antihypertensive medication can be added?

Add a Thiazide or Thiazide-Like Diuretic

For a patient already on telmisartan 80 mg and amlodipine 10 mg with uncontrolled blood pressure, add a thiazide or thiazide-like diuretic—specifically chlorthalidone 12.5-25 mg or hydrochlorothiazide 12.5-25 mg once daily 1, 2.

Rationale for This Recommendation

You currently have the patient on a maximally-dosed ARB (telmisartan 80 mg) and CCB (amlodipine 10 mg). The next step in the treatment algorithm is to complete the triple-combination therapy by adding the third major drug class: a diuretic 1.

Why a Diuretic is the Correct Choice

• Guideline-directed therapy: The 2024 ESC guidelines explicitly recommend triple-combination therapy consisting of an ARB (or ACE inhibitor), CCB, and thiazide/thiazide-like diuretic as the standard approach for uncontrolled hypertension 1
• Proven efficacy: Research demonstrates that adding hydrochlorothiazide 12.5 mg to telmisartan 80 mg/amlodipine 5 mg produces significant additional BP reduction (systolic/diastolic) and increases the proportion of patients achieving target BP <140/90 mmHg 3
• Single-pill combinations available: Telmisartan/amlodipine/hydrochlorothiazide fixed-dose combinations exist and improve adherence 3, 4

Specific Diuretic Recommendations

Preferred option: Chlorthalidone 12.5-25 mg once daily

• Chlorthalidone is preferred over hydrochlorothiazide due to its longer half-life and proven CVD outcome reduction in trials 2
• Start at 12.5 mg to minimize electrolyte disturbances

Alternative option: Hydrochlorothiazide 12.5-25 mg once daily

• If chlorthalidone is unavailable or not tolerated
• The 12.5 mg dose has been specifically studied with telmisartan/amlodipine combinations 3

Alternative option: Indapamide 1.25-2.5 mg once daily

• Another thiazide-like diuretic with proven efficacy
• Recent meta-analysis shows the triple combination of telmisartan/amlodipine/indapamide effectively reduces BP 4

Critical Monitoring Requirements

Electrolyte Monitoring is Essential

• Check serum potassium, sodium, and creatinine within 2-4 weeks after starting the diuretic
• Hypokalemia risk increases to approximately 9% with triple therapy versus 7% with dual therapy 4
• Hyponatremia risk increases to approximately 5% versus 3.7% 4
• Monitor uric acid levels, especially if the patient has gout history 2

Blood Pressure Monitoring

• Reassess BP in 1 month if possible, but maximal effect may take 4 weeks 5
• Target BP <140/90 mmHg for most patients (guidelines vary by age and comorbidities)

What Comes After Triple Therapy (If Still Uncontrolled)

If BP remains uncontrolled on maximally tolerated triple therapy (ARB + CCB + diuretic):

1. First, assess medication adherence before adding a fourth agent 1
2. Consider referral to hypertension specialist for resistant hypertension workup 1
3. Add spironolactone 25-50 mg once daily as the preferred fourth-line agent 1
   • Spironolactone is more effective than beta-blockers for resistant hypertension
   • Monitor potassium closely (risk of hyperkalemia with ARB + spironolactone)
4. Alternative fourth-line agents if spironolactone not tolerated 1:
   • Eplerenone 50-200 mg (may need twice daily dosing)
   • Beta-blocker (vasodilating types: carvedilol, nebivolol, labetalol)

Common Pitfalls to Avoid

• Don't add a second RAS blocker (ACE inhibitor + ARB combination is contraindicated) 1, 5
• Don't skip the diuretic and jump to spironolactone—complete standard triple therapy first 1
• Don't forget to check for secondary causes of hypertension if requiring 4+ medications
• Don't use potassium supplements routinely with this regimen without checking levels first (ARB already reduces potassium loss from diuretic) 2
• Watch for orthostatic hypotension, especially in elderly patients or those on dialysis 5